We’re excited to share that Xgene Pharmaceutical has announced positive topline results from their late-phase trial of XG005, an innovative non-opioid treatment for post-surgical pain. Lotus Clinical Research, in collaboration with Evolution Research Group, was proud to support this multi-center, placebo-controlled, Phase 2b study across multiple U.S. sites.

The trial showed that XG005 provided statistically significant pain relief in patients undergoing bunionectomy, with results indicating a reduction in pain intensity and opioid consumption. Notably, the high dose (1250 mg) of XG005 proved to be highly effective, reducing pain significantly compared to placebo.

We look forward to the continued development of XG005 and its potential to provide patients a safer, non-opioid alternative for acute pain relief.

For full details, read the press release here: News – Xgene Pharmaceutical Group.

#ClinicalTrials #PainManagement #NonOpioidTreatment #ClinicalResearch #LotusClinicalResearch